Immunologic mechanisms in the pathogenesis of rheumatoid arthritis

Journal of Clinical Rheumatology

Volumn 11, Issue 3 SUPPL., 2005, Pages

  Firestein, Gary S ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Autoimmunity; B cells; Cytokines; Immune complexes; Pathogenesis; Rheumatoid arthritis; T cells

Indexed keywords

ABATACEPT; ADALIMUMAB; AUTOANTIBODY; BIOLOGICAL RESPONSE MODIFIER; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; DISEASE COURSE; HUMAN; IMMUNOMODULATION; INFLAMMATION; JOINT DESTRUCTION; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVITIS; T LYMPHOCYTE ACTIVATION;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNITY; CYTOKINES; FIBROBLASTS; HUMANS; SYNOVIAL MEMBRANE; T-LYMPHOCYTES;

EID: 20844442966     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000166673.34461.33     Document Type: Review

References (42)

1. Sangha O. Epidemiology of rheumatic disease. Rheumatology (Oxford). 2000;39(suppl 2):3-12.
2. Dunlop DD, Manheim LM, Yelin EH, et al. The costs of arthritis. Arthritis Rheum. 2003;49:101-113.
3. Franklin EC, Holman HR, Muller-Eberhard HJ, et al. An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med. 1957;105:425-438.
4. Zvaifler NJ. The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol. 1973;16:265-336.
5. Stastny P. Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest. 1976;57:1148-1157.
6. Nepom GT, Byers P, Seyfried C, et al. HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum. 1989;32:15-21.
7. Weyand CM, Hicok KC, Conn DL, et al. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992;117:801-806.
8. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol. 1990;144: 3347-3353.
9. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003; 423:356-361.
10. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 1990;33:768-773.
11. Kouskoff V, Korganow AS, Duchatelle V, et al. Organ-specific disease provoked by systemic autoimmunity. Cell. 1996;87:811-822.
12. Korganow AS, Ji H, Mangialaio S, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999;10:451-461.
13. Matsumoto I, Staub A, Benoist C, et al. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science. 1999;286:1732-1735.
14. Ditzel HJ. The K/BxN mouse: a model of human inflammatory arthritis. Trends Mol Med. 2004;10:40-45.
15. Matsumoto I, Maccioni M, Lee DM, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol. 2002;3:360-365.
16. Ji H, Pettit A, Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 2002; 196:77-85.
17. Matsumoto I, Lee DM, Goldbach-Mansky R, et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum. 2003;48:944-954.
18. van Boekel MA, Vossenaar ER, van den Hoogen FH, et al. Auto-antibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res. 2002;4:87-93.
19. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific auto-antibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380-386.
20. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741-2749.
21. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101:273-281.
22. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000;43:1831-1835.
23. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/ peptide antibody assays in early rheumatoid arthritis for predicting five year radiographie damage. Ann Rheum Dis. 2003;62:120-126.
24. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004;50:709-715.
25. Firestein GS. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest. 2004;114: 471-474.
26. Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature. 2003;426:454-460.
27. Stuart RW, Racke MK. Targeting T cell costimulation in autoimmune disease. Exp Opin Ther Targets. 2002;6:275-289.
28. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305-334.
29. Kremer JM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol. 2005;11(suppl): S55-S62.
30. Udagawa N, Kotake S, Kamatani N, et al. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res. 2002;4:281-289.
31. Steiner G, Tohidast-Akrad M, Witzmann G, et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford). 1999;38:202-213.
32. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787-793.
33. Dolhain RJ, van der Heiden AN, ter Haar NT, et al. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 1996;39:1961-1969.
34. Janeway CA, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease, 5th ed. New York: Taylor & Francis Group; 2001.
35. Stamp LK, James MJ, Cleland LG. Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis? Immunol Cell Biol. 2004;82:1-9.
36. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999;42:963-970.
37. Koshy PJ, Henderson N, Logan C, et al. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis. 2002;61:704-713.
38. Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004;50:650-659.
39. Pap T, Muller-Ladner U, Gay RE, et al. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000;2:361-367.
40. Ospelt C, Neidhart M, Gay RE, et al. Synovial activation in rheumatoid arthritis. Front Biosci. 2004;9:2323-2334.
41. Muller-Ladner U, Kriegsmann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol. 1996;149:1607-1615.
42. Genovese MC. Biologic therapies in clinical development for the treatment of rheumatoid arthritis. J Clin Rheumatol. 2005;11(suppl):S45-S54.